David P. Steensma

David Steensma, a physician at Dana-Farber Cancer Institute in Boston, dives deep into the nuances of clonal hematopoiesis. He discusses how genetic mutations in stem cells can drive clonal dominance and the clinical implications for patient care. Key insights include the establishment of specialized clinics to manage these conditions and the importance of advanced sequencing technologies in cancer prevention. The conversation highlights how understanding these mechanisms can improve outcomes and foster better communication with patients.